<DOC>
	<DOCNO>NCT00877214</DOCNO>
	<brief_summary>The purpose study determine extend maintenance therapy Rituximab follicular maintenance therapy indolent mantle cell lymphoma advantage compare short maintenance therapy .</brief_summary>
	<brief_title>Significance Duration Maintenance Therapy With Rituximab Non-Hodgkin Lymphomas</brief_title>
	<detailed_description>Results several randomised study show clinical benefit maintenance therapy rituximab follicular lymphoma . The advantage maintenance therapy indolent mantle cell lymphoma - due low incidence diseases- well investigate . This study try determine significance extend maintenance therapy rituximab follicular lymphoma significance maintenance therapy indolent mantle cell lymphomas compare observation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients histological verify CD20positive BCellLymphoma follow entity : Follicular Lymphoma Grade 1 2 Lymphoplasmocytic lymphoma / Immunocytoma ( Morbus Waldenstr√∂m ) small cell lymphocytic lymphoma ( CLL without leukemic hemogram ) Marginal zone lymphoma , nodal extra nodal Mantle cell lymphoma No prior therapy cytotoxics , interferon monoclonal antibody Need therapy , except mantle cell lymphomas Stadium III IV Stadium II bulky disease ( &gt; 7 cm diameter , 3 lesion &gt; 5 cm ) General condition WHO 02 Age min . 18 year , max . 80 year Negative pregnancy test , contraceptives mandatory woman childbearing age Actual histology , old 6 month require Written informed consent Patients meet inclusion criterion Possibility primary radiation therapy curative intention Pretreatment , except single , localized radiation therapy ( radiation field large 2 adjacent lymph node region ) Comorbidities , exclude therapy accord protocol : severe , medicinal adjustable hypertension severe limit capacity heart ( NYHA III IV ) , lung ( WHOGrade III IV ) , liver kidney ( creatinin &gt; 2 mg/dl , GOT GPT bilirubin 3 x ULN ) , except cause lymphoma severe , medicinal adjustable diabetes mellitus active autoimmune disease active infection , require antibiotic therapy Patients proven HIVinfection Active replicate hepatitisInfection Severe psychiatric disease Lacking anticipated noncompliance Known hypersensitivity active component additives mouse protein Pregnant nursing woman Patients secondary malignancy malignant disease history , curative surgery doubtless assure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Bendamustine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Significance maintenance therapy</keyword>
	<keyword>Efficacy safety</keyword>
</DOC>